A two-step purification platform for efficient removal of Fab-related impurities: A case study for Ranibizumab

Antibodies (mAbs) and antibody fragments (Fabs) constitute one of the largest and most rapidly expanding groups of protein pharmaceuticals. In particular, antibody fragments have certain advantages over mAbs in some therapeutic settings. However, due to their greater chemical diversity, they are mor...

Celý popis

Podrobná bibliografie

Hlavní autoři:	Ozge Tatli, Yagmur Oz, Baran Dingiloglu, Duygu Yalcinkaya, Ezgi Basturk, Melis Korkmaz, Latif Akbulut, Derya Hatipoglu, Cansin Kirmacoglu, Buse Akgun, Kubra Turk, Orkun Pinar, Berna Sariyar Akbulut, Zeynep Atabay, Eda Tahir Turanli, Dilek Kazan, Gizem Dinler Doganay
Médium:	Artigo
Jazyk:	Inglês
Vydáno:	Elsevier 2023-11-01
Edice:	Heliyon
Témata:	Antibody fragment Pharmaceutical purification Biosimilar production Liquid chromatography Mass spectrometry
On-line přístup:	http://www.sciencedirect.com/science/article/pii/S2405844023082099
Tagy:	Přidat tag Žádné tagy, Buďte první, kdo vytvoří štítek k tomuto záznamu!